308 related articles for article (PubMed ID: 36519589)
1. The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
Rusarova N; Vitaskova D; Kalabova H; Ondruskova A; Purova D; Melichar B; Studentova H
Future Oncol; 2022 Dec; 18(38):4183-4192. PubMed ID: 36519589
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
[TBL] [Abstract][Full Text] [Related]
4. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S
Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.
Jeske S; Tagawa ST; Olowokure O; Selzer J; Giannakakou P; Nanus DM
Urol Oncol; 2011; 29(6):676-81. PubMed ID: 20451413
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer].
Bai GC; Song Y; Jin J; Yu W; He ZS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):686-691. PubMed ID: 34393229
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
9. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
Wenzel M; Borkowetz A; Lieb V; Hoffmann MA; Borgmann H; Höfner T; Dotzauer R; Neuberger M; Worst TS; von Hardenberg J; Linxweiler J; Klümper N
Urol Oncol; 2022 Dec; 40(12):538.e7-538.e14. PubMed ID: 36244915
[TBL] [Abstract][Full Text] [Related]
11. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
12. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
13. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
19. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
[TBL] [Abstract][Full Text] [Related]
20. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
Bouman-Wammes EW; van den Berg HP; de Munck L; Beeker A; Smorenburg CH; Vervenne WL; Coenen JLLM; Verheul HMW; Gerritsen WR; Van den Eertwegh AJM
Eur J Cancer; 2018 Feb; 90():1-9. PubMed ID: 29268139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]